Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 3/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.39 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 11/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23270564 | 0.91 | NT5E (0.45) | P2RX3P2RX1P2RX4NT5E | |
| SCHEMBL31078413 | 0.89 | P2RX3 (0.38) | P2RX3P2RX1P2RX4RXFP1PI4KA | |
| SCHEMBL31078493 | 0.88 | P2RX1 (0.31) | P2RX3P2RX1P2RX4 | |
| SCHEMBL23270520 | 0.85 | PI4KA (0.50) | P2RX3P2RX1P2RX4RXFP1PI4KA | |
| SCHEMBL31078280 | 0.85 | NT5E (0.35) | NT5E | |
| SCHEMBL31078334 | 0.83 | NT5E (0.46) | P2RX3P2RX1P2RX4RXFP1NT5E | |
| SCHEMBL22215066 | 0.81 | P2RX1 (0.47) | P2RX3P2RX1P2RX4RXFP1PI4KA | |
| SCHEMBL23270441 | 0.80 | NT5E (0.44) | P2RX3P2RX1P2RX4NT5E | |
| SCHEMBL23915001 | 0.79 | P2RX3 (0.54) | P2RX3P2RX1P2RX4RXFP1PI4KA | |
| SCHEMBL21882958 | 0.79 | P2RX3 (0.54) | P2RX3P2RX1P2RX4RXFP1PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331068-B2 | Compositions and methods for inhibiting CD73 | PELOTON THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-3810109-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING CD73 | PELOTON THERAPEUTICS INC (US) | 2024-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331068-B2 | Compositions and methods for inhibiting CD73 | ENTPD5, NT5E, ENTPD1 | P2RX3 37/4885P2RX1 53/4885P2RX4 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.